Trial Profile

Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Complications

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 21 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Solengepras (Primary)
Indications Parkinson's disease
Focus Registrational; Therapeutic Use
Acronyms ARISE
Sponsors Cerevance

Most Recent Events

12 May 2026 According to a Cerevance media release, Stuart H. Isaacson is the principal investigator of this trial
12 May 2026 According to a Cerevance media release, company announced completion of patient enrollment in the pivotal Phase 3 ARISE trial evaluating solengepras in Parkinson's disease and the closing of a $20 million Series C financing round and company is looking forward to see the data later this year.
02 Apr 2026 Planned End Date changed from 1 Mar 2026 to 1 Aug 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com